文献速递临床试验与 GCP基础与转化研究

青少年重型血友病B的AAV基因治疗Ⅰ期试验

Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial.
PubMed 文献 · Nat Med · 2026-09-16

这项多中心单臂Ⅰ期研究纳入11名12-18岁重型或中型重型血友病B青少年,单次输注BBM-H901(5×10^12 vg/kg)并随访52周。主要终点安全性显示无剂量限制性毒性,最常见不良事件为白细胞及中性粒细胞升高和激素相关皮疹。关键次要终点显示第52周FIX:C均值41.8 IU/dl,年化出血率从13.9降至0.5。

要点

  • 青少年重型血友病B患者接受BBM-H901后52周FIX:C均值达41.8 IU/dl。
  • 年化出血率从13.9降至0.5,提示初步疗效。
  • 安全性可管理,1例肝酶升高经免疫抑制治疗4周后恢复。

核心结论

  • BBM-H901在12-18岁重型或中型重型血友病B青少年中安全,并显示初步疗效。

研究设计与样本

  • 多中心、单臂、Ⅰ期研究,纳入11名12-18岁重型或中型重型血友病B青少年(FIX:C≤2 IU/dl)。
  • 所有受试者接受BBM-H901单次输注,剂量为5×10^12 vg/kg,随访52周。
  • 主要终点为安全性,关键次要终点包括第52周FIX:C和年化出血率。

主要发现

  • 研究全程未观察到剂量限制性毒性。
  • 最常见不良事件为白细胞计数升高、中性粒细胞计数升高及与糖皮质激素使用相关的皮疹。
  • 发生1例严重不良事件和2例3级不良事件。
  • 1名受试者出现肝功能异常,丙氨酸氨基转移酶197.0 U/l、天冬氨酸氨基转移酶75.0 U/l,免疫抑制治疗4周后恢复正常。
  • 第52周FIX:C均值(标准差)为41.8(30.1)IU/dl(一期法SynthASil),年化出血率从13.9降至0.5。

临床怎么用

  • 对于12-18岁重型或中型重型血友病B青少年,BBM-H901可作为一次输注的基因治疗选择,需监测肝功能和免疫抑制相关不良事件。

局限性

  • 单臂设计、样本量小(11例)、随访52周,疗效需更长期和对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adeno-associated virus (AAV)-mediated factor IX Padua gene therapy has demonstrated good safety and efficacy in adult patients with hemophilia B, but its safety and efficacy in adolescent patients with hemophilia B remain unknown. Here we report a multicenter, single-arm, phase 1 study involving 11 adolescent participants (aged 12-18 years) with severe or moderately severe hemophilia B (factor IX coagulant activity (FIX:C) ≤2 IU dl-1) in China. All of them received the AAV gene therapy BBM-H901 at a dose of 5 × 1012 vector genomes per kilogram of body weight and were then enrolled in a 52-week follow-up. The primary endpoint was safety. No dose-limiting toxicity was observed throughout the study. The most common adverse events included elevation of white blood cell count, elevation of neutrophil count and rash associated with corticosteroid use. One serious adverse event and two grade 3 adverse events occurred. Abnormal liver function was observed in one participant, with elevated alanine aminotransferase (197.0 U l-1) and aspartate aminotransferase (75.0 U l-1) levels, which returned to normal 4 weeks after immunosuppression therapy. The key secondary endpoints included the mean (s.d.) FIX:C at week 52 following infusion, which was 41.8 (30.1) IU dl-1 (one-stage SynthASil method), and the mean annualized bleeding rate, which decreased from 13.9 to 0.5. In this study, we show that the gene therapy drug BBM-H901 for hemophilia B is safe in adolescent patients, providing initial insights into its efficacy. ClinicalTrials.gov identifier: NCT05709288 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Xue F, Zhang A, Ju M, et al. Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial. Nat Med. 2026. PMID: 42749889. doi:10.1038/s41591-026-04636-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。